Document is current
Any future updates will be listed below
-
Authors
Brastianos, Priscilla K. https://orcid.org/0000-0003-4470-8425
Kim, Albert E.
Giobbie-Hurder, Anita https://orcid.org/0000-0003-2496-7737
Lee, Eudocia Q.
Lin, Nancy U.
Overmoyer, Beth https://orcid.org/0000-0003-4438-7000
Wen, Patrick Y.
Nayak, Lakshmi
Cohen, Justine V.
Dietrich, Jorg
Eichler, April
Heist, Rebecca S.
Krop, Ian
Lawrence, Donald
Ligibel, Jennifer
Tolaney, Sara https://orcid.org/0000-0002-5940-8671
Mayer, Erica https://orcid.org/0000-0001-5430-8957
Winer, Eric
Bent, Brittany
de Sauvage, Magali A.
Ijad, Nazanin
Larson, Juliana M.
Marion, Braxton
Nason, Sally
Murthy, Naina
Ratcliff, Sherry
Summers, Elizabeth J.
Mahar, Maura
Shih, Helen A.
Oh, Kevin
Cahill, Daniel P.
Gerstner, Elizabeth R.
Sullivan, Ryan J. https://orcid.org/0000-0001-5344-6645
- License Information
-
More Information
Article History
Received: 8 March 2023
Accepted: 9 May 2023
First Online: 2 June 2023
Competing interests
: P.K.B. consulted for Tesaro, Angiochem, Genentech-Roche, ElevateBio, Eli Lilly, SK Life Sciences, Pfizer, Voyager Therapeutics, Sintetica, MPM, Advise Connect Inspire, Kazia and Dantari, received institutional research funding (to MGH) from Merck, Mirati, Eli Lilly, Kinnate, BMS and Pfizer and has received honoraria from Merck, Medscape, Pfizer, and Genentech-Roche. B.O. has received clinical trial support from Incyte and Eisai. J.D. has served as a consultant for Amgen, Blue Earth Diagnostics and Unum Therapeutics and received research support (to MGH) from Novartis and Eli Lilly. R.S.H. consulted for AbbVie, Daichii Sankyo, EMD Serono, Lilly, Novartis, Regeneron, and Sanofi; and received institutional research funding (to MGH) from Abbvie, Agios, Corvus, Daichii Sankyo, Erasca, Exelixis, Lilly, Mirati, Novartis and Turning Point. P.Y.W. received institutional research funding (to DF/HCC) from AstraZeneca/Medimmune, Beigene, Celgene, Chimerix, Eli Lilly, Erasca, Genentech/Roche, Kazia, MediciNova, Merck, Novartis, Nuvation Bio, Puma, Servier, Vascular Biogenics and VBI Vaccines, and has served on the scientific advisory board for AstraZeneca, Bayer, Black Diamond, Celularity, Chimerix, Day One Bio, Genenta, Mundipharma, Novartis, Novocure, Nuvation Bio, Prelude Therapeutics, Sapience, Servier, Sagimet, Vascular Biogenics and VBI Vaccines. H.A.S. has served on the scientific advisory board for Advanced Accelerator Applications, and received institutional research funding (to MGH) from AbbVie. R.J.S. consulted for Novartis, BMS and Pfizer, and received institutional research funding (to MGH) from Merck. The remaining authors declare no competing interests.
